Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
Allergan Aesthetics (ABBV) will present 21 evidence-based e-posters at AMWC Monaco, March 26-28, 2026, covering clinical, real-world and preclinical research. Key highlights include investigational neurotoxin trenibotulinumtoxinE with rapid improvement as early as 8 hours and short 2-3 week duration, BOTOX Cosmetic real-world satisfaction and multimodal care trends, VYC-12L/VYC-20L hyaluronic acid data with up to 6 months of benefit, HA-CaHA durability to 18 months, and CoolSculpting molecular evidence for lasting fat reduction.
Allergan Aesthetics (NYSE:ABBV) introduced the concept of an "Undetectable† Era" for hyaluronic acid (HA) injectables at AMWC Monaco on March 26, 2026. Research of 12,000 consumers in nine countries found strong demand for subtle, natural-looking results and personalized treatment plans.
JUVÉDERM® is presented as a versatile HA portfolio supporting individualized, long-lasting, reversible outcomes and practitioner-led multimodal approaches such as AA Signature™ and MD Codes™ training.
AbbVie (NYSE: ABBV) announced a multi-year partnership with Major League Baseball beginning in the 2026 season to expand Striking Out Cancer league-wide. AbbVie will donate $20 per strikeout up to $1 million per season, with proceeds benefiting Stand Up To Cancer. The program launches March 25, 2026, and includes enhanced activations around marquee events and AbbVie presenting the 2026 Wild Card Series.
NImmune Biopharma will present preclinical and translational data on LANCL2-targeting therapeutics at IMMUNOLOGY2026 (April 15–19, 2026). Data show oral NIM-1324 and topical omilancor outperforming current psoriasis treatments in multiple mouse models, first-in-human NIM-1324 met primary and secondary endpoints, and NIM-1324 is Phase 2-ready for ulcerative colitis and other indications.
Findings highlight LANCL2-driven Treg enhancement, reduced pro-inflammatory mediators, improved phagocyte clearance, and translational blood signatures supporting target engagement.
Allergan Aesthetics (NYSE: ABBV) unveiled global consumer research from more than 12,000 respondents and is presenting an evolution of its AA Signature™ multimodal framework at AMWC 2026 in Monaco. Key findings: 62% find multiple treatments appealing, 59% favor structured multi-treatment plans, and 78% prefer long-term agreed plans. The company also highlighted that 74% intend to improve skin quality in the next 12 months and introduced AA Signature™ Skin360+ to integrate injectables with energy-based devices.
The program includes symposia, live injection sessions, a Global Medical Affairs symposium, and 21 scientific e-posters to support practitioner education and multimodal treatment planning.
AbbVie (NYSE: ABBV) announced positive topline Phase 1 multiple ascending dose results for ABBV-295 on March 9, 2026. ABBV-295, a long-acting amylin analog, produced dose-dependent mean weight reductions of -7.75% to -9.79% at week 12 (weekly dosing) and -7.86% to -9.73% at week 13 (alternate dosing), versus placebo ~-0.25%.
The study tested 2–14 mg doses, enrolled mostly male participants (88.3%), showed a favorable tolerability profile with no serious adverse events, and reported mostly mild gastrointestinal events early in treatment. Full data will be presented at a future scientific conference.
Allergan Aesthetics (NYSE:ABBV) released data on March 4, 2026 showing Medical Weight Loss (MWL) is reshaping aesthetic demand, with patients prioritizing facial appearance and volume restoration.
Key metrics: 67% changed goals toward appearance, 61% report midface volume loss, 81% of HCPs favor HA fillers, and 60% of GLP-1 users obtain medications from providers who also offer aesthetic services (up from 49%).
AbbVie (NYSE: ABBV) will participate in the Leerink Partners Global Healthcare Conference on Tuesday, March 10, 2026. Management will take part in a fireside chat at 10:20 a.m. Central Time. A live audio webcast will be available via AbbVie's Investor Relations site, with an archived edition posted later that day.
AbbVie (NYSE: ABBV) reported positive topline results from the Phase 3 AFFIRM study of risankizumab (SKYRIZI) subcutaneous induction in adults with moderately to severely active Crohn's disease on March 2, 2026. Co-primary endpoints at week 12 met: CDAI clinical remission 55% vs 30% and endoscopic response 44% vs 14% versus placebo (both p<0.0001). Among 12-week responders who continued maintenance, 67% achieved clinical remission and 57% achieved endoscopic response at week 24. Safety was consistent with known profile; most common adverse events were upper respiratory tract infection, abdominal pain and arthralgia.
AbbVie (NYSE: ABBV) will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026. Management will take part in a fireside chat at 10:10 a.m. Central Time. A live audio webcast and an archived edition will be available via AbbVie's investor site.